

United States District Court
District of Massachusetts

UNITED STATES OF AMERICA, ex)	
rel. CHRISTOPHER R. GOBBLE,)	
Plaintiff,)	
)	Civil Action No.
v.)	03-10395-NMG
)	
FOREST LABORATORIES, INC. and)	
FOREST PHARMACEUTICALS, INC.,)	
Defendants.)	

MEMORANDUM & ORDER

GORTON, J.

Plaintiff and qui tam relator Christopher Gobble ("Gobble") brings a personal claim for retaliatory termination against defendants Forest Laboratories, Inc. ("Forest Labs") and Forest Pharmaceuticals, Inc. ("Forest Pharmaceuticals") (together, "Forest") pursuant to the False Claims Act ("FCA"), 31 U.S.C. § 3730(h). Before the Court is Forest's motion to dismiss that claim.

I. Factual Background

The following allegations (which, for the purpose of this motion to dismiss, are taken as true) are from Gobble's fourth amended complaint. Gobble was a sales representative for Forest Pharmaceuticals from October, 2001 through June, 2002. During his employment, Gobble observed and subsequently complained to supervisors about two categories of improper conduct: 1) illegal

kickbacks (i.e., paying doctors for no other reason than to induce them to prescribe Celexa and Lexapro) and 2) off-label promotions of those drugs for use in children and adolescents. Gobble contends that this conduct violated the FCA and caused medical providers to submit false or fraudulent claims to government health insurance programs.

During his employment, Gobble worked closely with Stephen Jones ("Jones"), a senior sales representative, and Jason Richardson ("Richardson"), the Forest Pharmaceuticals Divisional Manager, both of whom, he claims, engaged in various wrongful acts. With respect to kickbacks, Gobble alleges that, inter alia, 1) Jones regularly paid speaker fees and other sums to doctors who prescribed a high volume of Celexa but performed no services for the fees and 2) Jones and Richardson routinely provided expensive meals, golf outings and other gifts for doctors and influential non-physicians to induce prescriptions for the subject drugs.

With respect to off-label promotions, Gobble claims that certain pediatric psychiatrists were targeted. At a December, 2001, sales meeting, for example, Forest allegedly provided sales representatives with a European study implying that Celexa should be prescribed for adolescents and told sales staff to use the study to promote the drug but never to leave any copies behind with doctors. Several pediatric psychiatrists were included on Gobble's "call panel".

Gobble contends that he was concerned about the perceived illegal conduct and thus inquired of his supervisors about it. In April and May, 2002, for instance, he claims that he told Richardson that Jones was paying doctors despite the fact that no services were being performed and that such actions constituted illegal kickbacks and inducements. Gobble also told another divisional manager, Jake Beale ("Beale"), about the kickbacks and discussed his concerns with another sales representative, Sally Grigsby ("Grigsby"), who confirmed Jones's kickback practices. Gobble then asked Grigsby to report what she had seen to Beale.

Regarding off-label promotions, Gobble claims that, during a car ride with Richardson, he "questioned" why pediatricians should be on his call list given that Celexa had no adolescent indications. He was concerned about the fact that representatives were encouraged to refer to the European study but not to leave any copies. Gobble states that he subsequently reiterated his concerns to Jones and Richardson but that, in general, his complaints were shrugged off.

In June, 2002, Gobble was fired for 1) submitting a false expense voucher and 2) purchasing gifts for a doctor with whom he had cancelled a golf outing. Although Gobble acknowledges that his actions were improper, he contends that Jones and Richardson advised him to do both, thereby setting him up to be fired pretextually instead of in retaliation for reporting improper practices. After he was fired, Gobble contacted Forest about

conducting a full investigation of his allegations and the grounds for which he was discharged. Forest's response was, according to Gobble, unsatisfactory and he has allegedly suffered numerous personal and professional setbacks since he was terminated.

II. Procedural History

Gobble filed his complaint in this qui tam action in March, 2003. The action was initially assigned to Chief Judge William Young before being reassigned to this session in June, 2004. After numerous continuances, the federal government filed a notice of intervention in November, 2008, and a complaint in February, 2009. Later that year, the parties notified the Court that they had reached a settlement and the Court entered a settlement order of dismissal in September, 2009. While the parties have attempted to work out the complicated details of the settlement, the Court has extended its order several times.

In the meantime, Gobble informed the Court that his individual claims against Forest are not covered by the qui tam settlement and that he intends to proceed accordingly. A scheduling order was entered in December, 2009. The following month, Gobble filed his fourth amended complaint and, in February, 2010, the defendants filed a motion to dismiss Count IV of that complaint. Gobble has opposed their motion and the defendants have submitted a reply.

In March, 2010, at a status conference convened to discuss the qui tam settlements, the Court invited oral argument on the pending motion to dismiss but neither party was prepared to go forward. As a result, the Court interposed questions to counsel and allowed the parties to file short supplemental memoranda in response thereto.

III. Analysis

A. Motion to Dismiss Standard

To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to "state a claim to relief that is plausible on its face." Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 570 (2007). In considering the merits of a motion to dismiss, the Court may look only to the facts alleged in the pleadings, documents attached as exhibits or incorporated by reference in the complaint and matters of which judicial notice can be taken. Nollet v. Justices of the Trial Court of Mass., 83 F. Supp. 2d 204, 208 (D. Mass. 2000) aff'd, 248 F.3d 1127 (1st Cir. 2000). Furthermore, the Court must accept all factual allegations in the complaint as true and draw all reasonable inferences in the plaintiff's favor. Langadinos v. American Airlines, Inc., 199 F.3d 68, 69 (1st Cir. 2000). If the facts in the complaint are sufficient to state a cause of action, a motion to dismiss the complaint must be denied. See Nollet, 83 F. Supp. 2d at 208.

B. Gobble's Retaliation Claim

Section 3730(h) of the FCA provides that

Any employee ... shall be entitled to all relief necessary to make that employee ... whole, if that employee ... is discharged, demoted, suspended, threatened, harassed, or in any other manner discriminated against in the terms and conditions of employment because of lawful acts done by the employee ... on behalf of the employee ... [or] others in furtherance of other efforts to stop 1 or more violations of this subchapter.

31 U.S.C. § 3730(h)(1). To establish a prima facie claim for retaliatory termination under the FCA, therefore, a plaintiff must show that 1) he engaged in "protected conduct", 2) the employer knew that the employee was engaged in such conduct and 3) the employee was discharged "because of" that protected conduct. United States ex rel. Karvelas v. Melrose-Wakefield Hosp., 360 F.3d 220, 235 (1st Cir. 2004).

Defendants contend that Gobble's complaint does not state a claim with respect to all three prongs. Each is considered in turn.

1. Protected Conduct

"Protected conduct" is to be interpreted broadly and the First Circuit defines it to mean

activities that reasonably could lead to an FCA suit[,] in other words, investigations, inquiries, testimonies or other activities that concern the employer's knowing submission of false or fraudulent claims for payment to the government.

Id. at 237. A plaintiff, however, need not have known that his

actions could lead to a qui tam suit under the FCA, or even that a False Claims Act existed, in order to demonstrate that he engaged in protected conduct. Id.

Here, defendants argue that engaging in protected conduct requires action "in furtherance of" an FCA suit and that Gobble alleges no such conduct. They say that is because 1) complaining to a supervisor is not protected conduct unless accompanied by concrete steps (not taken by Gobble) involved in prosecuting or assisting a qui tam suit and 2) the substance of plaintiff's complaints was not about fraud on (or the knowing submission of false claims to) the government but rather reporting non-compliance with the laws applicable to selling pharmaceuticals, which is a critical difference.

Gobble responds by focusing on the broad language of Karvelas. He retorts that an employee need not use magic words like "false claims" but need only show that the conduct about which the employee is complaining is capable of supporting an FCA claim. He alleges that kickbacks and off-label promotions are both subject to FCA liability and, therefore, his conduct in investigating and inquiring about such actions was protected.

Defendants reply that Gobble incorrectly interprets the law. They insist that the relevant question is not whether the plaintiff was complaining about events that could be a predicate for an FCA claim but whether the plaintiff was engaged in protected conduct (i.e., conduct aimed at exposing government

fraud) at the time of the alleged retaliation. They maintain that, notwithstanding any viability in Gobble's post-hoc theory that Forest was violating the FCA with kickbacks and off-label promotions, his actions while employed by Forest must be capable of reasonably being characterized as aimed at exposing fraud on the government and he cannot make that showing.

In their supplemental memoranda, the parties proffer similar arguments. Gobble contends that, unlike other circuits, the First Circuit does not consider the relator's subjective intent and only requires that, objectively, the subject matter of the relator's complaints could reasonably lead to an FCA case. Because kickbacks and off-label promotions can form the basis for an FCA action, Gobble's conduct was purportedly protected.

Defendants respond that, although they agree that subjective intent is not determinative and that an employee need not know that an FCA claim exists, the employee's conduct "must, objectively, be focused on or directed or aimed at exposing fraud against the government". Here, they argue that Gobble does not meet that test because 1) his conduct involved only internal complaints about regulatory non-compliance and not an investigation or inquiry and 2) the subject matter of Gobble's complaints did not concern the employer's knowing submission of false or fraudulent claims for payment to the government. Moreover, they insist that "protected conduct" does not automatically include any conduct that is capable of ultimately

leading to an FCA claim.

Both positions have been thoroughly delineated. On the one hand, Gobble correctly argues that the language in Karvelas is broad and his allegations can be fairly construed to allege inquiries that reasonably could (and did) lead to an FCA suit. On the other hand, Forest reasonably responds that being retaliated against for investigating or inquiring about an FCA violation requires some connection between the inquiries and fraud on the government. The fact that an employee might believe that he was fired for being a good corporate citizen and rooting out illegal conduct does not necessarily imply that he was fired for conduct taken in furtherance of efforts to avoid FCA violations.

The Court finds that, on balance, the defendants have failed to meet their considerable burden of proof in seeking the dismissal of Gobble's claim at this stage of the litigation. First, the definition of protected conduct in this Circuit is objective and broad and, as stated, can be read to incorporate Gobble's allegations. Cases from other circuits which do not employ the same test but rather utilize a standard that considers the subjective belief or intent of the relator or require more affirmative action on his part are inapposite. E.g., Fanslow v. Chicago Mfg. Ctr., Inc., 384 F.3d 469, 479-80 (7th Cir. 2004). See also Zahodnick v. Int'l Bus. Machs. Corp., 135 F.3d 911, 914 (4th Cir. 1997) (finding no protected conduct and criticizing

plaintiff for "never inform[ing] anyone that he was pursuing a qui tam action").

Second, the Court's reading of Karvelas differs from the defendants'. It does not hold (as defendants contend) that an employee's subject conduct "must, objectively, be focused on or directed or aimed at exposing fraud against the government". To be sure, Gobble's complaint does not explicitly tie his retaliation claim to fraud on the government but the complaint does generally describe how his inquiries support an FCA claim. Drawing all inferences in his favor and reading those allegations together with the retaliation claim, the Court finds that Gobble has alleged enough to survive a motion to dismiss.

Nor is the Court persuaded by the argument that Gobble merely complained about regulatory violations and that, under Karvelas and other cases, such inquiries cannot support a retaliation claim. In Karvelas, the Court held that the alleged regulatory violations about which the relator had inquired were not, without more, themselves actionable under the FCA. 360 F.3d at 234-35. See also United States ex rel. Hopper v. Anton, 91 F.3d 1261 (9th Cir. 1996). In that case, it logically followed that investigating conduct which is not actionable under the FCA could not reasonably lead to an FCA suit. Karvelas, 360 F.3d at 237 ("[C]orrecting regulatory problems ... is not actionable under the FCA in the absence of actual fraudulent conduct.") (citation and quotation marks omitted). Here, by contrast,

Gobble claims that his inquiries concerned conduct that was actionable under the FCA and thus his activities reasonably could have led (and did lead) to a viable FCA action.

Defendants' position also seems to ask too much of whistleblower plaintiffs, especially on a motion to dismiss. While Gobble did not connect all of the dots between alleged illegal kickbacks and off-label promotions and fraud on the government during his employment as a new sales representative at Forest or understand that the subject improprieties implicated such fraud (or include a statement to that effect in his complaint), the complaint is not therefore dismissible.

2. Knowledge

The second requirement for a valid FCA retaliation claim is that the employer knew that the employee was engaged in protected conduct. The defendants' requisite awareness "mirrors the kind of protected activity in which an employee must be engaged". Karvelas, 360 F.3d at 238 (citation and quotation marks omitted).

The Court is convinced that Gobble has adequately pled that the defendants were on notice of and knew about his protected conduct. His complaint contains several allegations of complaints and inquiries to his supervisors about the allegedly unlawful kickbacks and off-label promotions. Indeed, as Gobble's counsel stated at oral argument, it is reasonable to infer that Forest was in a position of superior knowledge and knew or should

have known that the improprieties about which Gobble inquired concerned possible FCA violations.

Thus, although Gobble did not, at the time, tell his supervisors that he was inquiring about fraud on the government, because the Court has found that he has adequately stated a claim of protected conduct, it also finds that the employer knew (or should have known) that he was engaged in such conduct.

3. Causation

Defendants also contend that Gobble cannot show that he was fired "because of" his protected conduct. In particular, they call his claims of pretext conclusory and speculative and maintain that Gobble can show only that he was fired shortly after complaining. Moreover, defendants assert that his argument is "patently implausible" because he admits that he was fired for wrongful conduct of false expense reports and purchasing gifts for a doctor.

Gobble responds that the timing of his firing and its nexus to his engagement in protected activity is sufficient at this stage to infer that he was fired for retaliatory reasons. He also alleges that he had received favorable evaluations and salary increases prior to his complaints which further support the conclusion that he was impermissibly fired.

Gobble has the better argument. His complaint alleges, with extensive and colorable support, that he was fired in retaliation

for his conduct and that the stated reasons were pretextual. That is enough to survive a motion to dismiss.

C. Dismissal of Forest Labs

Forest also contends that Gobble's complaint contains no basis for holding Forest Labs liable apart from the fact that it is the parent company of Forest Pharmaceuticals (for whom Gobble worked). Defendants argue that the retaliation claim cannot proceed against Forest Labs absent a valid veil-piercing theory which Gobble does not allege. Gobble responds that his complaint alleges sufficient contacts with Forest Labs including that 1) it was responsible for relevant ethics guidelines and 2) two Forest Labs employees were involved in his firing.

The Court will not dismiss the claim against Forest Labs at this stage.

ORDER

In accordance with the foregoing, defendants' motion to dismiss (Docket No. 90) is **DENIED**.

So ordered.

/s/ Nathaniel M. Gorton
Nathaniel M. Gorton
United States District Judge

Dated July 23, 2010

Publisher Information

Note* This page is not part of the opinion as entered by the court.

**The docket information provided on this page is for the benefit
of publishers of these opinions.**

1:03-cv-10395-NMG Gobble et al v. Forest Laboratories, Inc et al

Nathaniel M. Gorton, presiding

Date filed: 03/04/2003

Date terminated: 09/29/2009

Date of last filing: 07/23/2010

Attorneys

William F. Benson Sugarman, Rogers, representing Forest Laboratories, Inc. (Defendant)
Barshak & Cohen, P.C. 101 Merrimac Street
Boston, MA 02114-4737 617-227-3030 617-
523-4001 (fax) benson@srbc.com Assigned:

11/24/2009 ATTORNEY TO BE NOTICED

Jennifer C. Boal United States Attorney's representing Forest Pharmaceuticals, Inc. (Defendant)
USA (Plaintiff)

Office John Joseph Moakley Federal

Courthouse 1 Courthouse Way Suite 9200

Boston, MA 02210 617-748-3100 Assigned:

05/07/2003 TERMINATED: 05/24/2005 LEAD

ATTORNEY ATTORNEY TO BE NOTICED

Ty M. Bridges Harmon, Smith, Bridfes & representing Christopher R. Gobble (Plaintiff)

Wilbanks 1795 Peachtree Road, NE 350

Atlanta, GA 30309 404-881-1200 Assigned:

04/15/2003 ATTORNEY TO BE NOTICED

District of Columbia Washington D.C.

(Plaintiff)
Florida, State of (Plaintiff)
Hawaii, State of (Plaintiff)
Illinois, State of (Plaintiff)
Louisiana, State of (Plaintiff)
Massachusetts, Commonwealth of

(Plaintiff)
Nevada, State of (Plaintiff)
State of Delaware (Plaintiff)
Tennessee, State of (Plaintiff)
Texas, State of (Plaintiff)
USA (Plaintiff)
Virginia, Commonwealth of (Plaintiff)
California, State of (Plaintiff)
Forest Laboratories, Inc. (Defendant)

Andrew J. Ceresney Debevoise & Plimpton representing

919 Third Ave. New York, NY 10022-3902

212-909-6000 ajceresney@debevoise.com

Assigned: 08/14/2009 PRO HAC VICE

ATTORNEY TO BE NOTICED

Jeffrey Mark Cohen United States Attorney's representing

Office Suite 9200 1 Courthouse Way

Boston, MA 02210 617-748-3626 617-748-

3969 (fax) jeffrey.cohen@usdoj.gov

Assigned: 05/24/2005 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Forest Pharmaceuticals, Inc. (Defendant)
California, State of (Plaintiff)

District of Columbia Washington D.C.

(Plaintiff)
Florida, State of (Plaintiff)
Hawaii, State of (Plaintiff)
Illinois, State of (Plaintiff)
Louisiana, State of (Plaintiff)
Massachusetts, Commonwealth of

(Plaintiff)
Nevada, State of (Plaintiff)
State of Delaware (Plaintiff)
Tennessee, State of (Plaintiff)
Texas, State of (Plaintiff)
USA (Plaintiff)

Suzanne E. Durrell 180 Williams Avenue representing
Milton, MA 02186 617-333-9681

suzanne.durrell@verizon.net Assigned:

03/04/2003 LEAD ATTORNEY ATTORNEY

TO BE NOTICED

Virginia, Commonwealth of (Plaintiff)
Christopher R. Gobble (Plaintiff)
California, State of (Plaintiff)

District of Columbia Washington D.C.

(Plaintiff)
Florida, State of (Plaintiff)
Georgia, State of (Plaintiff)
Hawaii, State of (Plaintiff)
Illinois, State of (Plaintiff)
Indiana, State of (Plaintiff)
Louisiana, State of (Plaintiff)
Massachusetts, Commonwealth of

(Plaintiff)
Michigan, State of (Plaintiff)
Nevada, State of (Plaintiff)
New Hampshire, State of (Plaintiff)
New Jersey, State of (Plaintiff)
New Mexico, State of (Plaintiff)
New York, State of (Plaintiff)
Oklahoma, State of (Plaintiff)
Rhode Island, State of (Plaintiff)
State of Delaware (Plaintiff)
Tennessee, State of (Plaintiff)
Texas, State of (Plaintiff)
USA (Plaintiff)
Virginia, Commonwealth of (Plaintiff)
Wisconsin, State of (Plaintiff)
Christopher R. Gobble (Plaintiff)
Forest Laboratories, Inc. (Defendant)

Jyotin Hamid Debevoise & Plimpton, LLP representing
919 Third Avenue New York, NY 10022 212-

909-6000 jhamid@debevoise.com Assigned:

01/22/2010 LEAD ATTORNEY PRO HAC

VICE ATTORNEY TO BE NOTICED

Andrew Kanter Sugarman, Rogers, Barshak representing
& Cohen, P.C. 101 Merrimac Street 9th
Floor Boston, MA 02114 617-227-3030

Forest Pharmaceuticals, Inc. (Defendant)
Forest Laboratories, Inc. (Defendant)

Assigned: 08/12/2009 ATTORNEY TO BE

NOTICED

Kristin D. Kiehn Debevoise & Plimpton 919 representing Forest Pharmaceuticals, Inc. (Defendant)
Forest Laboratories, Inc. (Defendant)
Third Ave. New York, NY 10022-3902 212-
909-6000 kdkiehn@debevoise.com

Assigned: 08/14/2009 PRO HAC VICE

ATTORNEY TO BE NOTICED

Natasha C. Lisman Sugarman, Rogers, representing Forest Pharmaceuticals, Inc. (Defendant)
Forest Laboratories, Inc. (Defendant)
Barshak & Cohen 101 Merrimac Street 9th
Floor Boston, MA 02114 617 227-3030 617
523-4001 (fax) lisman@srbc.com Assigned:

08/12/2009 LEAD ATTORNEY ATTORNEY

TO BE NOTICED

Philip S. Marsteller 16 South Second Street representing Forest Pharmaceuticals, Inc. (Defendant)
Christopher R. Gobble (Plaintiff)
Richmond, VA 23219 804-775-0651

Assigned: 04/15/2003 ATTORNEY TO BE

NOTICED

California, State of (Plaintiff)
District of Columbia Washington D.C.

(Plaintiff)
Florida, State of (Plaintiff)
Hawaii, State of (Plaintiff)
Illinois, State of (Plaintiff)
Louisiana, State of (Plaintiff)
Massachusetts, Commonwealth of

(Plaintiff)
Nevada, State of (Plaintiff)
State of Delaware (Plaintiff)
Tennessee, State of (Plaintiff)
Texas, State of (Plaintiff)
USA (Plaintiff)
Virginia, Commonwealth of (Plaintiff)
Georgia, State of (Plaintiff)
Indiana, State of (Plaintiff)
Michigan, State of (Plaintiff)

New Hampshire, State of (Plaintiff)
New Jersey, State of (Plaintiff)
New Mexico, State of (Plaintiff)
New York, State of (Plaintiff)
Oklahoma, State of (Plaintiff)
Rhode Island, State of (Plaintiff)
Wisconsin, State of (Plaintiff)
Christopher R. Gobble (Plaintiff)

Gregg D. Shapiro Office of the United States representing
Attorney One Courthouse Way, Suite 9200
Boston, MA 02210 617-748-3366

gregg.shapiro@usdoj.gov Assigned:

10/04/2006 ATTORNEY TO BE NOTICED

Christopher K. Tahbaz Debevoise & Plimpton representing
919 Third Ave. New York, NY 10022-3902
212-909-6000 cktahbaz@debevoise.com

Assigned: 02/07/2008 PRO HAC VICE

ATTORNEY TO BE NOTICED

Robert M. Thomas, Jr. Thomas & Associates representing
280 Summer Street 5th Floor Boston, MA
02210-1131 617-371-1072 888-676-7420

(fax) rmt@thomasandassoc.net Assigned:

01/12/2010 ATTORNEY TO BE NOTICED

Mary Jo White Debevoise & Plimpton 919 representing
Third Ave. New York, NY 10022-3902 212-
909-6000 mjwhite@debevoise.com Assigned:

08/14/2009 PRO HAC VICE ATTORNEY TO

BE NOTICED

Marlan B. Wilbanks Wilbanks & Bridges LLP representing
3414 Peachtree Road NE Suite 2075
Atlanta, GA 30326 404-842-1075

mbw@wilbanks-bridgeslaw.com Assigned:

USA (Plaintiff)
Forest Laboratories, Inc. (Defendant)

Forest Pharmaceuticals, Inc. (Defendant)
Christopher R. Gobble (Plaintiff)

Forest Laboratories, Inc. (Defendant)

Forest Pharmaceuticals, Inc. (Defendant)
Christopher R. Gobble (Plaintiff)

04/15/2003 ATTORNEY TO BE NOTICED

California, State of (Plaintiff)
District of Columbia Washington D.C.

(Plaintiff)
Florida, State of (Plaintiff)
Hawaii, State of (Plaintiff)
Illinois, State of (Plaintiff)
Louisiana, State of (Plaintiff)
Massachusetts, Commonwealth of

(Plaintiff)
Nevada, State of (Plaintiff)
State of Delaware (Plaintiff)
Tennessee, State of (Plaintiff)
Texas, State of (Plaintiff)
USA (Plaintiff)
Virginia, Commonwealth of (Plaintiff)
Georgia, State of (Plaintiff)
Indiana, State of (Plaintiff)
Michigan, State of (Plaintiff)
New Hampshire, State of (Plaintiff)
New Jersey, State of (Plaintiff)
New Mexico, State of (Plaintiff)
New York, State of (Plaintiff)
Oklahoma, State of (Plaintiff)
Rhode Island, State of (Plaintiff)
Wisconsin, State of (Plaintiff)